PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
PTEN (phosphatase and tensin homologue, deleted on chromosome 10) is a tumor suppressor with dual phosphatase activity and mutations of its gene, PTEN, have been associated with many sporadic cancers and heritable neoplasia syndromes, including Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. However, accumulating evidence now shows that PTEN may have novel functions other than as a phosphatase. In the present study, we show that PTEN is able to autoregulate its expression through the stabilization of another tumor suppressor p53. We further show that PTEN enhances p53 transactivation, a relationship that requires the interaction between PTEN and p53 and is PTEN phosphatase independent. We show that cell lines from Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients with germ line PTEN promoter mutations in the vicinity of the p53-binding motifs have altered p53 regulation. This seems to be due to reduced PTEN stability and decreased PTEN-p53 interactions. Our data provide clues to better understand the regulation of PTEN expression and the possible mechanisms of the pathogenesis of the subset of Cowden syndrome individuals with germ line promoter variation and who lack mutations in the PTEN coding region and splice sites. Importantly, this mechanism also holds for those sporadic tumors that lack intragenic mutations but have hemizygous deletion of PTEN, which includes the promoter region as manifested by loss-of-heterozygosity of 10q markers. The importance of our observations is underlined by the broad spectrum of neoplasias that harbor somatic PTEN or p53 alterations, or both. (Cancer Res 2006; 66(2): 736-42)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Under oxidative stress, PTEN accumulates in the nucleus and can bind to p53, amplifying its function [89], [90].”
From Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease (2014) · cites this paper as [90]
Citations
Cites
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · cited 9×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodInfluentialOncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 9×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodInfluentialRegulation of PTEN Transcription by p53
Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., & Mak, T. W. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00323-9 · Cited by 912 · cited 9×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodInfluentialGermline mutations in PTEN are present in Bannayan-Zonana syndrome
Marsh, D. J., Dahia, P. L. M., Zheng, Z., Liaw, D., Parsons, R., Gorlin, R. J., & Eng, C. (1997) · Nature Genetics · doi:10.1038/ng0897-333 · Cited by 655 · cited 14×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodSelf-citationWhang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639 · cited 9×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodInfluentialFreeman, D. J., Li, A. G., Wei, G., Li, H.-H., Kertesz, N., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00021-7 · Cited by 515 · cited 8×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodInfluentialProtean PTEN: Form and Function
Waite, K. A., & Eng, C. (2002) · The American Journal of Human Genetics · doi:10.1086/340026 · Cited by 457 · cited 9×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodSelf-citationKurose, K., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X.-P., & Eng, C. (2002) · Nature Genetics · doi:10.1038/ng1013 · Cited by 418 · cited 9×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodSelf-citationPerren, A., Weng, L.-P., Boag, A. H., Ziebold, U., Thakore, K., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 378 · cited 9×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodInfluentialSelf-citationPTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy
Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., & Donner, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108302200 · Cited by 351 · cited 9×
“p53 (1-363) is more stable than the wild-type, as reported before (14).”
BackgroundMethodInfluential
Cited by
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
PTEN: Tumor Suppressor and Metabolic Regulator
Chen, C.-Y., Chen, J., He, L., & Stiles, B. L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00338 · Cited by 583
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
“Phosphatase-independent function, such as direct binding and transactivation of p53 (Tang and Eng 2006), may also contribute to its melanoma-suppressive effects.”
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
Georgescu, M.-M. (2010) · Genes & Cancer · doi:10.1177/1947601911407325 · Cited by 482
Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression
Mouw, J. K., Yui, Y., Damiano, L., Bainer, R. O., Lakins, J. N., Acerbi, I., Ou, G., Wijekoon, A. C., Levental, K. R., Gilbert, P. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3497 · Cited by 396
“Reporter assays, using the proximal promoter region of PTEN 26,27 containing homeobox consensus binding sites, confirmed that luciferase activity was enhanced after co-transfection with increasing amounts of a wild-type but not a DNA binding domain mutant N255T HOXA9 (DNA BM) or by HOXA10 (Fig.”
Metadata
- Authors
- Tang, Y., & Eng, C.
- Affiliations
- Cleveland Clinic Research (US)
- University of Cambridge (GB)
- Venue
- Cancer Research
- Published
- 2006-01-15
- Volume
- 66
- Issue
- 2
- Pages
- 736-742
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1995726115
- Cited by
- 97
- References
- 18
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 7
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PTEN, p53, protein stabilization, p53 transactivation, Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, loss of heterozygosity, tumor suppressor regulation
- MeSH terms
- Gene Expression Regulation, Hamartoma Syndrome, Multiple, Humans, Promoter Regions, Genetic, Syndrome, Tumor Suppressor Protein p53, Germ-Line Mutation, PTEN Phosphohydrolase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-1557
- The paper
- Tang, Y., & Eng, C. (2006). PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-1557
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.